ALKS vs BMRN · P/E 14, rev $1.56B vs P/E 40, rev $2.85B
Alkermes Plc (ALKS) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the ALKS and BMRN stock pages for the full models.
Not investment advice.